Cargando…

Frequent activation of EGFR in advanced chordomas

BACKGROUND: Chordomas are rare neoplasms, arising from notochordal remnants in the midline skeletal axis, for which the current treatment is limited to surgery and radiotherapy. Recent reports suggest that receptor tyrosine kinases (RTK) might be essential for the survival or proliferation of chordo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dewaele, Barbara, Maggiani, Francesca, Floris, Giuseppe, Ampe, Michèle, Vanspauwen, Vanessa, Wozniak, Agnieszka, Debiec-Rychter, Maria, Sciot, Raf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372284/
https://www.ncbi.nlm.nih.gov/pubmed/22613809
http://dx.doi.org/10.1186/2045-3329-1-4
_version_ 1782235323429814272
author Dewaele, Barbara
Maggiani, Francesca
Floris, Giuseppe
Ampe, Michèle
Vanspauwen, Vanessa
Wozniak, Agnieszka
Debiec-Rychter, Maria
Sciot, Raf
author_facet Dewaele, Barbara
Maggiani, Francesca
Floris, Giuseppe
Ampe, Michèle
Vanspauwen, Vanessa
Wozniak, Agnieszka
Debiec-Rychter, Maria
Sciot, Raf
author_sort Dewaele, Barbara
collection PubMed
description BACKGROUND: Chordomas are rare neoplasms, arising from notochordal remnants in the midline skeletal axis, for which the current treatment is limited to surgery and radiotherapy. Recent reports suggest that receptor tyrosine kinases (RTK) might be essential for the survival or proliferation of chordoma cells, providing a rationale for RTK targeted therapy. Nevertheless, the reported data are conflicting, most likely due to the assorted tumor specimens used for the studies and the heterogeneous methodological approaches. In the present study, we performed a comprehensive characterization of this rare entity using a wide range of assays in search for relevant therapeutic targets. METHODS: Histopathological features of 42 chordoma specimens, 21 primary and 21 advanced, were assessed by immunohistochemistry and fluorescent in situ hybridization (FISH) using PDGFRB, CSF1R, and EGFR probes. Twenty-two of these cases, for which frozen material was available (nine primary and 13 advanced tumors), were selectively analyzed using the whole-genome 4.3 K TK-CGH-array, phospho-kinase antibody array or Western immunoblotting. The study was supplemented by direct sequencing of KIT, PDGFRB, CSF1R and EGFR. RESULTS: We demonstrated that EGFR is frequently and the most significantly activated RTK in chordomas. Furthermore, concurrent to EGFR activation, the tumors commonly reveal co-activation of alternative RTK. The consistent activation of AKT, the frequent loss of the tumor suppressor PTEN allele, the recurrent activation of upstream RTK and of downstream effectors like p70S6K and mTOR, all indicate the PI3K/AKT pathway as an important mediator of transformation in chordomas. CONCLUSIONS: Given the complexity of the signaling in chordomas, combined treatment regimens targeting multiple RTK and downstream effectors are likely to be the most effective in these tumors. Personalized therapy with careful selection of the patients, based on the molecular profile of the specific tumor, is anticipated.
format Online
Article
Text
id pubmed-3372284
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33722842012-06-12 Frequent activation of EGFR in advanced chordomas Dewaele, Barbara Maggiani, Francesca Floris, Giuseppe Ampe, Michèle Vanspauwen, Vanessa Wozniak, Agnieszka Debiec-Rychter, Maria Sciot, Raf Clin Sarcoma Res Research BACKGROUND: Chordomas are rare neoplasms, arising from notochordal remnants in the midline skeletal axis, for which the current treatment is limited to surgery and radiotherapy. Recent reports suggest that receptor tyrosine kinases (RTK) might be essential for the survival or proliferation of chordoma cells, providing a rationale for RTK targeted therapy. Nevertheless, the reported data are conflicting, most likely due to the assorted tumor specimens used for the studies and the heterogeneous methodological approaches. In the present study, we performed a comprehensive characterization of this rare entity using a wide range of assays in search for relevant therapeutic targets. METHODS: Histopathological features of 42 chordoma specimens, 21 primary and 21 advanced, were assessed by immunohistochemistry and fluorescent in situ hybridization (FISH) using PDGFRB, CSF1R, and EGFR probes. Twenty-two of these cases, for which frozen material was available (nine primary and 13 advanced tumors), were selectively analyzed using the whole-genome 4.3 K TK-CGH-array, phospho-kinase antibody array or Western immunoblotting. The study was supplemented by direct sequencing of KIT, PDGFRB, CSF1R and EGFR. RESULTS: We demonstrated that EGFR is frequently and the most significantly activated RTK in chordomas. Furthermore, concurrent to EGFR activation, the tumors commonly reveal co-activation of alternative RTK. The consistent activation of AKT, the frequent loss of the tumor suppressor PTEN allele, the recurrent activation of upstream RTK and of downstream effectors like p70S6K and mTOR, all indicate the PI3K/AKT pathway as an important mediator of transformation in chordomas. CONCLUSIONS: Given the complexity of the signaling in chordomas, combined treatment regimens targeting multiple RTK and downstream effectors are likely to be the most effective in these tumors. Personalized therapy with careful selection of the patients, based on the molecular profile of the specific tumor, is anticipated. BioMed Central 2011-07-25 /pmc/articles/PMC3372284/ /pubmed/22613809 http://dx.doi.org/10.1186/2045-3329-1-4 Text en Copyright ©2011 Dewaele et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Dewaele, Barbara
Maggiani, Francesca
Floris, Giuseppe
Ampe, Michèle
Vanspauwen, Vanessa
Wozniak, Agnieszka
Debiec-Rychter, Maria
Sciot, Raf
Frequent activation of EGFR in advanced chordomas
title Frequent activation of EGFR in advanced chordomas
title_full Frequent activation of EGFR in advanced chordomas
title_fullStr Frequent activation of EGFR in advanced chordomas
title_full_unstemmed Frequent activation of EGFR in advanced chordomas
title_short Frequent activation of EGFR in advanced chordomas
title_sort frequent activation of egfr in advanced chordomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372284/
https://www.ncbi.nlm.nih.gov/pubmed/22613809
http://dx.doi.org/10.1186/2045-3329-1-4
work_keys_str_mv AT dewaelebarbara frequentactivationofegfrinadvancedchordomas
AT maggianifrancesca frequentactivationofegfrinadvancedchordomas
AT florisgiuseppe frequentactivationofegfrinadvancedchordomas
AT ampemichele frequentactivationofegfrinadvancedchordomas
AT vanspauwenvanessa frequentactivationofegfrinadvancedchordomas
AT wozniakagnieszka frequentactivationofegfrinadvancedchordomas
AT debiecrychtermaria frequentactivationofegfrinadvancedchordomas
AT sciotraf frequentactivationofegfrinadvancedchordomas